RUMORED BUZZ ON AP-III-A4

The medications with elamipretide as the key raw content have entered the 3rd period of clinical apply.Elamipretide triacetate is an aromatic-cationic tetrapeptide that targets the mitochondrial intima and is particularly an inhibitor of cardiolipin peroxidase. It very easily penetrates cell membranes and is used in therapeutic trials investigating